TiGenix NV (Euronext Brussels: TIG) has announced that
Dirk Büscher and José Terencio resigned from their position as board member, effective as of
July 31, 2015.
Dirk Büscher and José Terencio are the CEO and COO respectively of Gri-Cel SA, a fully owned
subsidiary of Grifols, a world leader in plasma-derived therapeutics.
The board would like to thank them for their support since their appointment in December 2013.
TiGenix NV (Euronext Brussels: TIG) is an advanced biopharmaceutical company focused on
developing and commercialising novel therapeutics from its proprietary platform of allogeneic, or
donor-derived, expanded stem cells. Two products from this technology platform are currently in
clinical development. Cx601 is in Phase III for the treatment of complex perianal fistulas in Crohn’s
disease patients. Cx611 is in Phase IIb for early rheumatoid arthritis, and has completed a Phase I
sepsis challenge trial. Effective as of July 31, 2015, TiGenix acquired Coretherapix, whose lead
cellular product (AlloCSC-01) is currently in a Phase II clinical trial in acute myocardial infarction
(AMI). Coretherapix is planning to initiate the clinical evaluation of AlloCSC-01 in the chronic setting
as well and is also involved in the pre-clinical development of a pharmaceutical formulation of growth
factors to treat AMI. Finally, TiGenix also developed ChondroCelect, an autologous cell therapy
product for cartilage repair of the knee, which was the first Advanced Therapy Medicinal Product
(ATMP) to be approved by the European Medicines Agency (EMA). From June 2014, the marketing
and distribution rights of ChondroCelect have been exclusively licensed to Sobi for the European
Union (except for Finland, where it is distributed by the Finnish Red Cross Blood Service), Norway,
Russia, Switzerland and Turkey, and the countries of the Middle East and North Africa. TiGenix is
headquartered in Leuven (Belgium) and has operations in Madrid (Spain). For more information,
please visit www.tigenix.com